INVESTIGADORES
MARCIANO Sebastian
artículos
Título:
Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin
Autor/es:
RIDRUEJO E1; SOLANO A; SEBASTIAN MARCIANO; GALDAME O; ADROVER R; COCOZZELLA D; DELETTIERES D; MARTÍNEZ A; ADRIAN GADANO; MANDÓ OG; SILVA MO
Revista:
ANNALS OF HEPATOLOGY
Editorial:
MEXICAN ASSOC HEPATOLOGY
Referencias:
Año: 2011 p. 452 - 457
ISSN:
1665-2681
Resumen:
BACKGROUND AND AIMS:Genetic variations in the interleukin 28B (IL28B) gene have been associated with viral response to PEG-interferon-α/ribavirin (PR) therapy in hepatitis C virus (HCV) genotype 1 infected patients from North America, Europe and Asia. The importance of these IL28B variants for Argentine patients remains unknown.MATERIAL AND METHODS:IL28B host genotypes (rs8099917 and rs12979860) were determined in a population of Argentine patients with European ancestry. Results were analyzed looking for their association with sustained virologic response (SVR) to PR therapy and compared with other baseline hosts´ biochemical, histological and virological predictors of response.RESULTS:We studied 102 patients, 60% were men, and 40% of them were rs8099917 TT and 18% rs12979860 CC. Mean baseline serum HCV RNA was 1.673.092 IU/mL and mean F score was: 2.10 ± 1.18 (21% cirrhotic). SVR rate was higher in rs8099917 TT genotypes (55%) when compared to GT/GG (25%) (p = 0.002) and in rs1512979860 CC (64%) than in CT/TT (30%) (p = 0.004). The univariate analysis showed that rs8099917 TT (OR 3.7; 95 %CI 1.5-8.7; p = 0.002), rs12979860 CC (OR 4.6; 95%CI 1.5-13.7; p = 0.006), low viral load (OR 4.6; 95% CI 1.7-12.6; p = 0.002) and F0-2 (OR 8.5; 95% CI 2.3-30.6; p = 0.001) were significantly associated with SVR. In the multivariate analysis, rs12979860 CC, rs8099917 TT, viral load < 400.000 IU/mL and F0-2 were associated with SVR rates (p = 0.029, p = 0.012, p = 0.013 and p = 0.004, respectively).CONCLUSION:IL28B host genotypes should be added to baseline predictors of response to PR therapy in Latin American patients with European ancestry.